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936Objective: Recent reports from Europe and the United States have suggested that patients presenting for open
surgery with a significant history of atrial fibrillation (AF) have inferior early and late outcomes if AF is left
untreated. On the other hand, there is reluctance among surgeons to treat AF surgically, especially when atriot-
omies may be required otherwise, which is the case with aortic valve replacement (AVR) or coronary artery by-
pass grafting (CABG). The objective of this study was to explore the potential impact of the addition of the Cox
Maze III procedure on short- and long-term outcomes of patients when combined with AVR or CABG.
Methods: Since 2005, 485 patients have undergone the Cox Maze III procedure at Inova Heart and Vascular
Institute, 95 of whom had a full Cox Maze III with an AVR or CABG (Cox Maze III/AVR ¼ 30; Cox Maze
III/CABG ¼ 47; Cox Maze III/AVR/CABG ¼ 18). In addition, 4255 patients with no history of AF underwent
AVR or CABG without surgical ablation (AVR ¼ 422; CABG ¼ 3518; AVR/CABG ¼ 315). Data from our
CABG, valve, and AF registries were used for analyses. Patients with and without the Cox Maze III were pro-
pensity score matched using a 0.10 caliper to improve balance on clinical and demographic variables. Differ-
ences in perioperative and postoperative outcomes by group were evaluated using the Fisher exact test, and
a Kaplan–Meier survival analysis was completed. Health-related quality of life (Short Form 12) was obtained
at baseline and 6 months post-surgery (n ¼ 72).
Results: All 95 patients who underwent the Cox Maze III were propensity score matched with patients who did
not undergo the Cox Maze III. Mean age (t ¼ 0.3, P ¼ .79) and European System for Cardiac Operative Risk
Evaluation score (t ¼1.8, P ¼ .07) were similar between the groups. There were no significant differences
in major postoperative morbidities between the groups despite the Cox Maze III group being on bypass longer
(164.4 vs 108.8minutes; t¼9.8,P<.001). Pacemaker implantationwas significantly higher in the CoxMaze III
group (P¼ .03). Survival during follow-up (mean¼ 35 months) was not different between patients who did and
did not undergo the Cox Maze III procedure (log rank¼ 0.49, P¼ .48). Improvement in physical health-related
quality of life was similar for both groups (F ¼ 0.01, P ¼ .94). At 1 year, 94% of the patients (60/64) who
underwent the Cox Maze III procedure were in sinus rhythm (81% off class I and III antiarrhythmic drugs).
Conclusions: The addition of the CoxMaze III procedure to AVR or CABG did not convey an increase in major
morbidity and perioperative risk. Patients who underwent the Cox Maze III procedure demonstrated similar
survival over time with improvement in health-related quality of life. The Cox Maze III should not be denied
to patients in whom the cardiac surgical procedure does not include atriotomies because of the perceived in-
creased operative risk. The Cox Maze III may significantly improve their outcome. (J Thorac Cardiovasc
Surg 2012;143:936-44)Several large studies, including the Framingham study, have
shown that atrial fibrillation (AF) is associated with an in-
creased risk for mortality and morbidity.1-7 In the past
decade, studies from Europe and the United States havee Inova Hear and Vascular Institute, Cardiac Surgery Research, Falls Church,
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The Journal of Thoracic and Cardiovascular Surgsuggested that patients who present for cardiac surgery
with a significant history of AF have reduced survival
over time if AF is left untreated.8-10 Other studies have
also found that patients who present with AF have worse
perioperative outcomes, including a higher incidence of
perioperative stroke and mortality.8,10-13 The association
between preoperative AF and reduced survival and
increased morbidity led to the recommendation to include
surgical correction of AF while surgical revascularization
is being performed.9,14,15
Gammie and colleagues16 published a study based on the
Society of Thoracic Surgeons’ database, which demon-
strated that only 38% of patients presenting for cardiac sur-
gery while experiencing AF underwent any type of
corrective surgical ablation concomitantly with a valve orery c April 2012
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HRQL ¼ health-related quality of life
ISMICS ¼ International Society of Minimally
Invasive Cardiac Surgery
OR ¼ odds ratio
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Mcoronary bypass surgery. Fifty-two percent of patients un-
dergoing mitral valve surgery underwent concomitant sur-
gical correction of AF. However, only 28% of patients
with a concomitant aortic valve procedure and only 24%
of patients with concomitant isolated coronary artery by-
pass grafting (CABG) had concomitant surgical ablation.16
The patients least likely to have preoperative AF, those un-
dergoing isolated CABG, were also least likely to have their
AF treated, and this is despite evidence that it may improve
outcome.14,16 A possible explanation for such findings may
be related to surgeons’ concern of increased morbidity
associated with the Cox Maze procedure, especially when
performing aortic valve replacement (AVR) and CABG
where left atriotomy is not otherwise required. Recent
guidelines published by the International Society for
Minimally Invasive Cardiothoracic Surgery demonstrated
that the addition of surgical ablation is not associated with
an increased risk of morbidity (level A evidence);
however, scant literature is available on the combination
of AVR, CABG, and surgical ablation.
The aims of the present study were (1) to explore whether
the addition of a full Cox Maze III procedure to AVR or
CABG has a negative impact on patient perioperative out-
comes and (2) to assess the potential impact of surgical cor-
rection of AF on long-term survival.
MATERIALS AND METHODS
Since 2005, 585 patients have undergone surgical ablation by multiple
surgeons at Inova Heart and Vascular Institute. A total of 485 patients un-
derwent a Cox Maze III procedure using cryothermal energy alone or in
combination with bipolar radiofrequency technology.17,18 Ninety-five
patients underwent a full Cox Maze III procedure with an AVR or
CABG (Cox Maze III/AVR ¼ 30; Cox Maze III/CABG ¼ 47; Cox
Maze III/AVR/CABG ¼ 18). In addition, 4255 patients who were not
experiencing preoperative AF underwent AVR or CABG without surgical
ablation (AVR ¼ 422; CABG ¼ 3518; AVR/CABG ¼ 315). Data from
our CABG, valve, and AF registries were merged through a statistical
platform (SAS 9.1, SAS Institute Inc, Cary, NC) with data obtained
from our local Society of Thoracic Surgeons’ database. All patients
who underwent the Cox Maze III were prospectively followed at 3, 6,
9, 12, 18, and 24 months and then yearly thereafter. Rhythm was verified
with electrocardiography and 24-hour Holter.19 This study was approved
by the Inova Heart and Vascular Institute’s review board (numbers 6.037
and 6.022).The Journal of Thoracic and CaCox Maze Procedure
The Cox Maze procedure and its respective lesion set are a source of
confusion for 2 reasons: (1) the multiple iterations of the procedure starting
with Cox Maze I to the recent advent of the Cox Maze III/IV and (2) the
transition from a procedure carried out using a cut-and-sew technique to
the current use of an ablative energy source to create the lesion set. Because
the Cox Maze procedure is an electrophysiologic concept, the lesion set
and the way the lesions were created (ie, cut-and-sew vs ablative energy
sources) are key. The Cox Maze procedure performed on all patients in
this report is the Cox Maze III as described by Dr James Cox
(Figure 1).17,18Health-Related Quality of Life
Health-related quality of life (HRQL) was obtained at baseline and 6
months post-surgery. HRQL was evaluated at baseline and follow-up using
the Short-Form 12, which has long been considered a reliable and validated
instrument for use across many disease populations and is easy to admin-
ister being particularly adept for use in self-report situations.20 The family
of Short Form instruments has been used and validated in the cardiac sur-
gery population. The instrument measures 8 domains and 2 summary mea-
sures: physical component summary and mental component summary.
Scores range from 0 to 100, and the summary scores are standardized to
a mean of 50 and a standard deviation of 10.20 A higher score indicates bet-
ter HRQL and can be compared with age group norms. Our program is cur-
rently structured so that all patients who undergo the surgical ablation
procedure are asked to participate in our HRQL program, in which they
complete a survey preoperatively; at 3, 6, and 12 months postoperatively;
and yearly thereafter.Data Analysis
All patients were included in a first set of analyses to determine whether
the addition of the Cox Maze III procedure affected outcomes. Because of
differences in preoperative characteristics between the patients who did
and did not undergo the Cox Maze procedure, all analyses were adjusted
for the following covariates: age, gender, body mass index, ejection frac-
tion, diabetes, chronic pulmonary disease, previous valve surgery, previous
CABG, New York Heart Association class 3 and 4, AVR, CABG, emer-
gency surgery, bypass time, cross-clamp time, and perioperative transfu-
sion of blood products. Dichotomous outcomes, such as permanent
stroke and postoperative renal failure, were evaluated usingmultivariate lo-
gistic regression, and length of stay was evaluated using multivariate linear
regression. Survival during follow-up was also analyzed using Cox propor-
tional hazard model regression adjusted for the same set of clinical
covariates.
Patients who did and did not undergo the Cox Maze III procedure were
then propensity score matched using a 0.10 caliper with exact matching on
AVR and CABG to improve balance on preoperative clinical and demo-
graphic variables (Figure 2) including age, gender, body mass index, ejec-
tion fraction, diabetes, chronic pulmonary disease, previous valve surgery,
previous CABG, New York Heart Association class 3 and 4, AVR, CABG,
and emergency surgery. Differences in perioperative and postoperative out-
comes by groupwere evaluated using chi-square or Fisher exact test for cat-
egoric variables and Student t test or Mann–Whitney test for continuous
measures. Kaplan–Meier analysis was completed to compare cumulative
survival between the Cox Maze III group and the non-Cox Maze III group.
Changes in HRQL from baseline to 6 months were evaluated via repeated-
measures analyses of variance. A priori power analyses, with alpha set at
0.05 (2-tailed) and power set at 80%, revealed N ¼ 95 per group was suf-
ficient for effect sizes in between small and medium, which was reasonable
for most outcomes evaluated in this study.
Continuous data are presented as mean  standard deviation, and cate-
goric data are presented as frequency (%) unless otherwise noted. All anal-
yses were conducted using SPSS version 17.0 (SPSS Inc, Chicago, Ill).rdiovascular Surgery c Volume 143, Number 4 937
FIGURE 1. Cox Maze III lesion set. SPV, Superior pulmonary vein; LAA, left atrial appendage; LUPV, left upper pulmonary vein; LLPV, left lower pul-
monary vein; RUPV, right upper pulmonary vein; RLPV, right lower pulmonary vein.
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MRESULTS
Full Sample Results
The group of patients who presented with AF undergoing
the Cox Maze procedure (n ¼ 95) using cryothermia alone
or combined with bipolar radiofrequency ablation technol-
ogy was significantly different from the patients who pre-
sented to surgery with no AF (n ¼ 4255) on several
preoperative characteristics, including older age, fewer
with a history of myocardial infarction, fewer with diabetes,
higher ejection fraction, and higher European System for
Cardiac Operative Risk Evaluation score (Table 1).
In unadjusted analyses, the Cox Maze group was similar
to the non-Cox Maze group on perioperative permanent
stroke (1.1% vs 1.4%, P ¼ 1.00), prolonged ventilator
time (>24 hours) (6.3% vs 6.1%, P¼ .83), renal failure re-
quiring dialysis (1.1% vs 1.2%, P ¼ 1.00), readmissions
within 30 days of discharge (12.6% vs 8.3%, P ¼ .14),
and operative mortality (within 30 days; 1.1% vs 1.7%,
P ¼ 1.00). The Cox Maze group did have significantly
more patients who developed perioperative pneumonia
(5.3% vs 1.9%, P ¼ .04) and reoperation for bleeding
(5.0% vs 2.0%, P ¼ .046) compared with the non-Cox
Maze group, although none of the bleeding was related to
the atriotomies or left atrial appendage amputation. Length
of stay was significantly longer for the Cox Maze group938 The Journal of Thoracic and Cardiovascular Surgthan the non-Cox Maze group (median [interquartile
range] ¼ 6 [6] vs 4 [3], Z ¼7.1, P<.001). The length of
stay difference was attributed to slow recovery of sinus
rhythm and delayed anticoagulation treatment after surgery.
Multivariate analyses revealed that the addition of the
Maze procedure did not predict poorer perioperative out-
comes, except for perioperative pneumonia (odds ratio
[OR], 3.80; P ¼ .02), and the Maze procedure was related
to longer length of hospital stay (t ¼ 2.52, P ¼ .01; Table
2). No patients in the Cox Maze group experienced a deep
sternal wound infection. Addition of the Maze procedure
also did not predict receipt of both intraoperative blood
products (OR, 0.70; confidence interval [CI], 0.40–1.21,
P ¼ .20) or postoperative blood products (OR, 0.67; CI,
0.42–1.09; P ¼ .10) after adjustment for clinical covariates
in the multivariate analyses. Cox proportional hazards re-
gression found no difference in survival for patients with
and without the Maze procedure (hazard ratio, 0.97; CI,
0.47–2.01; P ¼ .93).
Propensity Score–Matched Results
All 95 patients undergoing the Cox Maze III were pro-
pensity score matched to a patient not undergoing the Cox
Maze III. Preoperative characteristics, such as age
(t ¼ 0.3, P ¼ .79) and European System for Cardiacery c April 2012
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FIGURE 2. Jitter plot indicating the distribution of propensity scores for
patients who underwent the CoxMaze III (treatment units) and thematched
patients who did not undergo the Cox Maze III (control units).
TABLE 2. Results of multivariate analyses of the full sample
(N ¼ 4350) to determine the effect on perioperative outcomes from
the addition of the Cox Maze III/IV procedure to the aortic valve
replacement and coronary artery bypass grafting procedures
OR 95% CI P value
Permanent stroke 0.55 0.07–4.35 .57
Prolonged ventilation (>24 h) 0.78 0.31–1.93 .59
Pneumonia 3.80 1.27–11.38 .02
Renal failure requiring
dialysis
0.76 0.09–6.20 .80
Reoperation for bleeding 2.09 0.81–5.41 .13
Length of stay (d) t ¼ 2.52 0.42–3.36 .01
Readmissions within 30 d 1.24 0.64–2.39 .53
Operative death 0.34 0.04–2.72 .31
Ad et al Perioperative ManagementOperative Risk Evaluation score (t ¼1.8, P ¼ .07), were
similar between the groups after propensity score matching
(Table 3). There were no significant differences in perioper-
ative and postoperative morbidities between the groups
(Table 4) despite the Cox Maze III group being on bypassTABLE 1. Perioperative characteristics of all patients (N ¼ 4350)
Cox Maze III
procedure
n ¼ 95
No Cox Maze III
procedure
n ¼ 4255
P
value
Age, y 68.2  9.0 63.6  10.9 <.001
Female 20 (21) 955 (22) .75
Body mass index 28.9  4.6 29.3  8.0 .64
NYHA class 3 and 4 7 (7) 453 (11) .40
Ejection fraction 57  11 54  11 .03
History of MI 18 (19) 1742 (41) <.001
Chronic pulmonary disease 16 (17) 569 (13) .36
Diabetes 24 (25) 1563 (37) .02
euroSCORE (additive) 6.33  2.49 4.85  3.36 <.001
Previous valve surgery 2 (2) 27 (0.6) .13
Previous CABG 4 (4) 141 (3) .56
Emergency surgery 0 224 (5) .02
Redo surgery 6 (6) 159 (4) .18
Aortic valve surgery 48 (51) 737 (17) <.001
CABG 65 (68) 3833 (90) <.001
No. of bypass grafts 2.5  1.0 3.1  1.0 <.001
Perfusion time 164.4  39.9 97.4  35.2 <.001
NYHA, New York Heart Association; MI, myocardial infarction; euroSCORE, Euro-
pean System for Cardiac Operative Risk Evaluation; CABG, coronary artery bypass
grafting.
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Mlonger (164.4 vs 108.8 minutes; t ¼9.8, P<.001). Length
of stay was longer in the CoxMaze III group compared with
the non-Cox Maze III group (Z ¼4.4, P<.001). Addition
of the Maze procedure also did not predict receipt of intra-
operative blood products (OR, 0.83; CI, 0.28–2.54; P¼ .75)
or postoperative blood products (OR, 0.63; CI, 0.25–1.57;
P ¼ .32) in the propensity score–matched groups. There
were 6 patients in the CoxMaze group with pacemakers im-
planted during the perioperative period (6%) compared
with no patients in the non-Cox Maze group who received
pacemakers (P ¼ .03). Survival during follow-up
(mean ¼ 35  21 months) was not different between pa-
tients with and without the Cox Maze III procedure (log
rank, 0.49; P ¼ .48; Figure 3).
Long-Term Follow-up Results for the Cox Maze
Group
Seventy-six patients were eligible for 12-month follow-
up, 3 patients asked to withdraw from follow-up, and 3 pa-
tients had no more available data, leaving 70 patients with
full clinical information. A total of 66 of 70 patients
(94%) were in sinus rhythm (81% in normal sinus rhythm
and not taking class I and III antiarrhythmic medications).
Thirty patients (43%) were not taking warfarin at 12
months post-surgery. Seventeen patients (57%) still taking
warfarin at 12 months had other clinical indications, such as
a history of deep vein thrombosis or pulmonary embolism.
After the blanking period, no patients had an embolic stroke
during the first 12 months of follow-up.
Health-Related Quality of Life
HRQLwas captured both at baseline (preoperative) and 6
months post-surgery for a subset of 72 propensity score-
matched patients. The groups were similar on HRQL at
baseline on both the physical component summary
(t ¼ 0.7, P ¼ .46) and mental component summary
(t ¼0.6, P ¼ .58). Physical HRQL significantly increased
from baseline to 6 months post-surgery (F¼ 11.8; P<.001;
Figure 3), with improvement in physical componentrdiovascular Surgery c Volume 143, Number 4 939
TABLE 3. Perioperative characteristics of the propensity score–
matched groups
Cox Maze III
procedure
n ¼ 95
No Cox Maze III
procedure
n ¼ 95
P
value
Age 68.2  9.0 68.6  10.0 .79
Female 20 (21) 20 (21) 1.00
Body mass index 28.9  4.6 28.1  5.5 .25
NYHA class 3 and 4 7 (7) 7 (7) 1.00
Ejection fraction 57  11 57  12 .94
History of MI 18 (19) 31 (33) .05
Chronic pulmonary disease 16 (17) 15 (16) 1.00
Diabetes 24 (25) 27 (28) .62
euroSCORE (additive) 6.3  2.5 5.6  3.2 .07
Previous valve surgery 2 (2) 2 (2) 1.00
Previous CABG 4 (4) 3 (3) 1.00
Emergency surgery 0 0 —
Redo surgery 6 (6) 5 (5) 1.00
Aortic valve surgery 48 (51) 48 (51) 1.00
CABG 65 (68) 65 (68) 1.00
No. of bypass grafts 2.5  1.0 2.8  1.1 .09
Perfusion time 164.4  39.9 108.8  37.7 <.001
NYHA, New York Heart Association; MI, myocardial infarction; euroSCORE, Euro-
pean System for Cardiac Operative Risk Evaluation; CABG, coronary artery bypass
grafting.
TABLE 4. Postoperative complications comparison between
propensity score–matched patients who underwent a concomitant
Cox Maze procedure and those without a Cox Maze procedure
Cox Maze III
procedure
n ¼ 95
No Cox Maze III
procedure
n ¼ 95
P
value
Permanent stroke 1 (1) 1 (1) 1.00
Prolonged ventilation (>24 h) 6 (6) 6 (6) 1.00
Pneumonia 5 (5) 2 (2) .44
Renal failure requiring
dialysis
1 (1) 1 (1) 1.00
Reoperation for bleeding 5 (5) 5 (5) 1.00
AF during stay 38 (40) 22 (23) .01
AF at discharge 17 (18) 0 <.001
Length of stay (d)* 6 (6) 5 (3) <.001
Readmissions within 30 d 12 (13) 10 (11) .82
Operative death 1 (1) 0 1.00
*Median (interquartile range), evaluated with Mann–Whitney test.
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tal HRQL did not significantly improve at 6 months post-
surgery (F ¼ 1.1, P ¼ .31), and this pattern did not differ
between groups (F ¼ 0.05, P ¼ .83; Figure 4).
DISCUSSION
This study suggests that applying the CoxMaze III lesion
set using cryothermia and bipolar radiofrequency in con-
junction with AVR or CABG was not associated with a sig-
nificant increase in major perioperative morbidity.
Although the Cox Maze group was found to have a higher
incidence of pneumonia postoperatively, this difference
was no longer present when patients were propensity score
matched. Length of stay and pacemaker implantation re-
mained significantly different between the groups even after
propensity score matching. This study also demonstrated
similar long-term survival when patients with AF undergo-
ing a Cox Maze procedure concomitantly with AVR or
CABG were compared with patients without AF undergo-
ing only AVR or CABG.
In an earlier analysis of the Framingham data, Kannel
and colleagues4 determined that AF was associated with
coronary artery disease. Several investigators have found
that patients with coronary artery disease and AF are at
a higher long-term risk for a coronary artery disease event
to include death.7,21 Other studies have also found that the
development of AF after a myocardial infarction can lead
to worse outcomes, including death.1,2,5
Several reports have indicated that patients presenting to
cardiac surgery with significant AF are at risk for higher940 The Journal of Thoracic and Cardiovascular Surgperioperativemorbidity and inferior long-term outcome.8-10
It is suggested that patients presenting to surgery with AF
represent a sicker group of patients, and therefore such
inferior outcome may not be surprising.14 The increased
risk associated with AF is reflected in the Society of Tho-
racic Surgeons’ database version 2.63 that incorporated
AF or flutter into the risk algorithm.22
Cardiac surgeons are facing 2 major dilemmas when op-
erating on patients for AVR or CABG who present for sur-
gery with AF. The first is related to patient selection and
whether to intervene and surgically ablate AF. The second
is what type of approach and lesion set should be applied.
The first cut-and-sew Maze procedure was performed 25
years ago, but the majority of studies related to its impact
are observational.17,18,23 In a recent consensus statement,
the International Society of Minimally Invasive Cardiac
Surgery (ISMICS) published a set of recommendations
for concomitant AF ablation based on the best evidence in
the literature.15 The ISMICS Consensus recommendations
are as follows: Concomitant surgical ablation is recommen-
ded to increase the incidence of sinus rhythm both at short-
and long-term follow-up (class 1, level A) to improve
ejection fraction and exercise tolerance (class 2a, level A)
and to reduce the risk of stroke and thromboembolic events,
to improve long-term survival (class 2a, level A). The rec-
ommendations are clear about the potential benefits of AF
surgical ablation but lack the ability of addressing patient
selection for the procedure, and this is especially important
when dealing with high-risk patients. However, our study
and others including the ISMICS statement and the Society
of Thoracic Surgeons’ data may suggest that the addition of
surgical ablation is not associated with increased operative
risk with the added benefit of higher rates of sinus
rhythm.15,16 In their extensive report, Gammie and
colleagues16 found that the only significant difference inery c April 2012
FIGURE 3. Kaplan–Meier survival curves comparing cumulative survival between patients with and without the Cox Maze III procedure.
Ad et al Perioperative Management
P
Mperioperative outcome was a higher pacemaker rate in the
surgical ablation group (7.1% vs 5.94%, P ¼ .0158).16
Damiano and colleagues24 reported excellent outcomes in
their small series of patients who underwent the Cox
Maze procedure concomitantly with CABG. In their series
of patients (n¼ 47), Damiano and colleagues found that the
perioperative complication rate was no different for the pa-
tients who did not have the Cox Maze procedure but under-
went an isolated CABG procedure and suggested that the
Cox Maze procedure should be presented as an option to
treat AF at the time of coronary artery bypass surgery.
In the current study, both the multivariate model and the
propensity score–matched analysis revealed no differences
in major morbidities between the groups. The only out-
comes that were significantly different even in the propen-
sity score–matched analysis were length of stay and new
pacemaker insertion. These 2 outcomes are somewhat re-
lated because of higher rates of nodal rhythm after a success-
ful Cox Maze procedure. The nodal rhythm results in
a ‘‘wait, watch, and see period’’ that may ultimately end
in pacemaker implantation for those that remain in a brady-
cardiac or nodal rhythm but does prolong the length of stay.
This waiting period also delays the initiation of anticoagu-
lation therapy, which may also hold up a patient’s discharge
from the hospital while awaiting a therapeutic international
normalized ratio.
The dilemma regarding the appropriate lesion set is an
important one that has not been addressed by a large-scale
randomized control study. However, a few publications, in-
cluding ours, demonstrated the potential advantage ofThe Journal of Thoracic and Cabiatrial lesion set over lesions confined to the left atrium
only when measuring the rate of return to sinus rhythm.25,26
On the basis of data from other studies, it is clear that limited
ablation confined to the left atrium only and especially
bilateral pulmonary vein isolation is not as effective in
patients with more complex AF and an enlarged left
atrium.27 Bilateral pulmonary isolation using bipolar radio-
frequency clamps is therefore tempting in the set-up of AVR
or CABG; however, surgeons should be selective because
many of these patients have persistent and long-standing
persistent AF combined with an enlarged left atrium.
The current study assessed the potential impact of the
Cox Maze III procedure when added to AVR or CABG.
As discussed, the addition of the Maze procedure necessi-
tates left and right atriotomies and therefore may be signif-
icant. The results of our study are encouraging and indicate
that the Cox Maze procedure is a safe and effective treat-
ment option that should be considered for patients who
present for CABG or AVR with AF. This cohort of patients
also demonstrates potential benefits and impact on long-
term survival. These facts make it imperative that patients
who present for surgical revascularization and AVR with
AF be evaluated for appropriate treatment to include surgi-
cal ablation and the Cox Maze procedure using appropriate
ablation devices.
As mentioned earlier, another encouraging finding of this
study was that survival was high in both study groups and
not significantly different between groups. In addition, the
return to sinus rhythm rate was relatively high for the surgi-
cal ablation group.rdiovascular Surgery c Volume 143, Number 4 941
FIGURE 4. HRQL improvement from pre-surgery to 6 months post-surgery. HRQL, Health-related quality of life.
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This study has several limitations that should be ac-
knowledged. The study is not a prospective randomized
study. It was conducted at a center well versed in the Cox
Maze procedure and with a high volume of CABG and
AVR surgeries. Thus, our findings may not be relevant to
low-volume centers with less experience in the combined
procedure.942 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
The addition of the Cox Maze III procedure to an AVR or
CABG did not convey an increased operative risk. Patients
who underwent the Cox Maze III demonstrated similar sur-
vival over timewith improvement in HRQL despite being in
AF before the procedure. The Cox Maze III should not be
denied to patients in whom the cardiac surgical procedure
does not include atriotomies because of the perceivedery c April 2012
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Mincreased operative risk. The Cox Maze III may signifi-
cantly improve their outcome.
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Dr John Doty (Murray, Utah). This study represents a propen-
sity-based analysis of adding surgical ablation to AVR and coro-
nary bypass. These are procedures that typically do not require
an atriotomy like a mitral valve operation. This shows that adding
a concomitant modified CoxMaze operation will have similar out-
comes but does not increase mortality and supports the safety and
efficacy of AF ablation operations.
I have 3 areas I would like you to clarify. First, I would recom-
mend you use the terminology ‘‘modified Cox Maze III’’ because
I believe that you use both cryoablation and radiofrequency. Can
you explain the percentage of patients you used for each of those
and how your group selects which energy modality that you use?
Dr Ad. I disagree with you on the definition. It is not a modified
Cox Maze procedure. The Cox Maze procedure is a principle, and
the CoxMaze III procedure is a set of lesions that are being applied
as a template and it does not matter how you deliver the lesions.
The terminology of a modified Cox Maze procedure is confusing
because it does not matter how you perform the entire lesions of
the Cox Maze procedure, radiofrequency, cryotherapy, and so
on. It is a principle that we should all account for. The Cox
Maze III procedure is a concept. I disagree with the terminology
of modified, and I am clear about it whenever I give a talk on
the topic.
In this series, the patients had the Cox Maze procedure lesion
set. Basically, in the past we used a combined bipolar radiofre-
quency ablation and cryotherapy. On the basis of our observation
with bipolar radiofrequency ablations related to reconnections as
published in a few articles in the past few years, we moved away
from that. Currently, all of our patients are now are being treated
with cryothermal energy.
Dr Doty. Second, your midterm results for restoration of sinus
rhythm are excellent. How do you measure that, and has there been
a difference between the radiofrequency and cryoablation cases
over time?
Dr Ad. Basically there is no difference between the different
energy sources as of yet, but we still follow all the patients. We de-
veloped our own registry and a follow-up system that is based on 3,
6, 9, 12, 18, and 24 months, and yearly thereafter, and at each time
point the patients are measured with electrocardiogram and 24-
hour Holter monitoring. However, at 6 and 24 months they are
also getting a 1-week Holter monitor. The results reported in this
article are based only on electrocardiogram and Holter monitoringrdiovascular Surgery c Volume 143, Number 4 943
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Mbecause not all patients agree to wear a monitor for 1 week at 6 and
24 months. To just level the playing field, those reports are per
electrocardiogram and Holter monitoring, and Heart Rhythm So-
ciety guidelines are being used, meaning that any event more
than 30 seconds is a failure.
Dr Doty. Finally, as you mentioned, some surgeons are reluc-
tant to add an ablation procedure, even those with small incisions
using alternative energy because of the perceived risk of bleeding
and prolonged bypass. Could you elaborate on your series of pa-
tients and results with that, particularly among your own partners?
You mentioned that you do ablation in almost all of your patients,
but you are having different results from the rest of the group.
Dr Ad. I think that is one of the key points. True prospective
randomized studies looking at multiple centers are lacking. We
just submitted an abstract to the Society of Thoracic Surgeons
on a scoring system in which we score 1 and 0 using different vari-
ables, such as older age and EF, and then we factor in the surgeon
experience. What we found is that the percentage of patients in
whom the Maze procedure was performed is decreasing when
the surgeon experience is limited or the complexity of the case
is higher. This resulted in more patients directed to me, and now
I am performing approximately 90% to 95% of those procedures
for our group; it is the same process with other procedures when
you get into this subspecialization within the group. The real an-
swer should come with an effort looking into a prospective ran-
domized study, and I know there is such an effort through the
Cardiothoracic Surgery Network and the National Institutes of944 The Journal of Thoracic and Cardiovascular SurgHealth–sponsored study. It is an important study because the ques-
tion is important for choosing who should receive AF and who
should receive extra care. If you just do the aortic valve, should
you open the left atrium for a fullMaze procedure or offer a limited
procedure with a lower success rate and perceived lower risk? On
the basis of my latest experience, my personal approach is that the
sicker the patient, the more beneficial it is to add the Maze proce-
dure because you can restore AV synchrony, evenwith pacing, dur-
ing the perioperative period. We do not deal with high ventricular
response rate, arrhythmias, and such. It is easier to manage those
patients. Yes, you do extend surgery specifically for CABG and
AVR, but only 30 to 45 minutes, which is insignificant with the
kind of myocardial preservation we have today. This article is
showing that together with the long-term benefit, it should offer
better outcome to patients with aortic and coronary artery disease.
With the cardiopulmonary bypass management, we have to deal
with cardioplegia. I think adding 30 to 45 minutes of bypass
time is not as big a deal as it was 10 years ago.
Dr John Chen (Honolulu, Hawaii). Are you treating this group
of patients, the AVR group, the same as your mitral valve group
with AF in your practice?
Dr Ad. Unless they have new-onset AF and a left atrium less
than 3.5 cm, which for the subgroup of patients who are not in-
cluded in this article, we perform a full Maze procedure in all of
them, yes. For those with new-onset AF and a small left atrium,
we are performing only pulmonary vein isolation and AVR or
CABG.ery c April 2012
